47 related articles for article (PubMed ID: 8691457)
1. Correction to "Steric Blockade of Oxy-Myoglobin Oxidation by Thiosemicarbazones: Structure-Activity Relationships of the Novel PPP4pT Series''.
Wijesinghe TP; Kaya B; Gonzálvez MA; Harmer JR; Gholam Azad M; Bernhardt PV; Dharmasivam M; Richardson DR
J Med Chem; 2024 Apr; 67(8):6893. PubMed ID: 38597697
[No Abstract] [Full Text] [Related]
2. Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study.
Islam MA; Barshetty MM; Srinivasan S; Dudekula DB; Rallabandi VPS; Mohammed S; Natarajan S; Park J
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139117
[TBL] [Abstract][Full Text] [Related]
3. A convenient method for synthesis of terpyridines
Karimi F; Yarie M; Zolfigol MA
RSC Adv; 2020 Jul; 10(43):25828-25835. PubMed ID: 35518593
[TBL] [Abstract][Full Text] [Related]
4. Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.
Plamthottam S; Sun D; Van Valkenburgh J; Valenzuela J; Ruehle B; Steele D; Poddar S; Marshalik M; Hernandez S; Radu CG; Zink JI
J Biol Inorg Chem; 2019 Aug; 24(5):621-632. PubMed ID: 31250199
[TBL] [Abstract][Full Text] [Related]
5. Porphyrins as ligands for
Aguilar-Ortíz E; Jalilian AR; Ávila-Rodríguez MA
Medchemcomm; 2018 Oct; 9(10):1577-1588. PubMed ID: 30429966
[TBL] [Abstract][Full Text] [Related]
6. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
Le TM; Poddar S; Capri JR; Abt ER; Kim W; Wei L; Uong NT; Cheng CM; Braas D; Nikanjam M; Rix P; Merkurjev D; Zaretsky J; Kornblum HI; Ribas A; Herschman HR; Whitelegge J; Faull KF; Donahue TR; Czernin J; Radu CG
Nat Commun; 2017 Aug; 8(1):241. PubMed ID: 28808226
[TBL] [Abstract][Full Text] [Related]
7. Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention.
Kowol CR; Miklos W; Pfaff S; Hager S; Kallus S; Pelivan K; Kubanik M; Enyedy ÉA; Berger W; Heffeter P; Keppler BK
J Med Chem; 2016 Jul; 59(14):6739-52. PubMed ID: 27336684
[TBL] [Abstract][Full Text] [Related]
8. Eco-Friendly Synthesis of Some Thiosemicarbazones and Their Applications as Intermediates for 5-Arylazothiazole Disperse Dyes.
Gaffer HE; Khalifa ME
Molecules; 2015 Dec; 20(12):21982-91. PubMed ID: 26690111
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Zeidner JF; Karp JE; Blackford AL; Smith BD; Gojo I; Gore SD; Levis MJ; Carraway HE; Greer JM; Ivy SP; Pratz KW; McDevitt MA
Haematologica; 2014 Apr; 99(4):672-8. PubMed ID: 24362550
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
11. Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.
Wang F; Jiao P; Qi M; Frezza M; Dou QP; Yan B
Curr Med Chem; 2010; 17(25):2685-98. PubMed ID: 20586723
[TBL] [Abstract][Full Text] [Related]
12. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity.
Nieland TJ; Shaw JT; Jaipuri FA; Duffner JL; Koehler AN; Banakos S; Zannis VI; Kirchhausen T; Krieger M
Biochemistry; 2008 Jan; 47(1):460-72. PubMed ID: 18067275
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of new copper thiosemicarbazone complexes with an ONNS quadridentate system: cell growth inhibition, S-phase cell cycle arrest and proapoptotic activities on cisplatin-resistant neuroblastoma cells.
Zhang H; Thomas R; Oupicky D; Peng F
J Biol Inorg Chem; 2008 Jan; 13(1):47-55. PubMed ID: 17909866
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.
Liu MC; Lin TS; Cory JG; Cory AH; Sartorelli AC
J Med Chem; 1996 Jun; 39(13):2586-93. PubMed ID: 8691457
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.
Liu MC; Lin TS; Sartorelli AC
J Med Chem; 1992 Oct; 35(20):3672-7. PubMed ID: 1433178
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone.
Liu MC; Lin TS; Penketh P; Sartorelli AC
J Med Chem; 1995 Oct; 38(21):4234-43. PubMed ID: 7473550
[TBL] [Abstract][Full Text] [Related]
18. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo.
Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC
Adv Enzyme Regul; 1995; 35():55-68. PubMed ID: 7572354
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
